non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients aged over 20 years old 2)Advanced or postoperative recurrence non-small cell lung cancer 3)Pembrolizumab plus platinum combination chemotherapy is planned as clinical practice. 4)The proportion of linear shadows, reticular abnormalities, or ground-glass abnormalities are less than 10% of all lung fields. 5) Written informed consent is obtained.
Exclusion criteria
Exclusion criteria: 1)Patients with history of drug induced pneumonitis. 2)Patients who has increased infiltration other than lung cancer within 1 month. 3)Patients with interstitial pneumonitis with UIP pattern on computed tomography. 4)Patients with interstitial pneumonitis associated with collagen diseases. 5)Pregnant women and patients who may be pregnant or breastfeeding. 6)Patients who are judged to be inappropriate for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The probability of pneumonitis in treatment of pembrolizumab plus platinum-based chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Objective response rate 2) Disease control rate 3) Relapse free survival 4) Severity of pneumonitis 5) Provability of pneumonitis during observation period 6) Time to occurrence of pneumonitis 7) Probability of occurrence of adverse events | — |
Countries
Japan
Contacts
Public ContactNaoko Katsurada
Kobe University Graduate School of Medicine Division of Respiratory Medicine, Department of Internal Medicine
Outcome results
None listed